<SEC-DOCUMENT>0001655759-22-000029.txt : 20220805
<SEC-HEADER>0001655759-22-000029.hdr.sgml : 20220805
<ACCEPTANCE-DATETIME>20220805161216
ACCESSION NUMBER:		0001655759-22-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220805
DATE AS OF CHANGE:		20220805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		221140960

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arvn-20220804.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:45999cf6-02eb-416a-9d0a-8f65ab11b7f5,g:111baa97-bb12-408d-a1db-041cb338d317,d:79ad90fd7c4540fa9a3ef29aa494d30e--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20220804</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV80L2ZyYWc6MTFjN2Y0ODEyOWZhNDdmNzhkNDlhNGE5MjFiODMzNmEvdGFibGU6YTZiN2MzY2I1ODQ5NGIwZmI4MTk3MDc1ZTVhM2QzOTIvdGFibGVyYW5nZTphNmI3YzNjYjU4NDk0YjBmYjgxOTcwNzVlNWEzZDM5Ml8wLTEtMS0xLTM1NTE3_26bb8f1b-8be1-4149-9f27-3e52fcb8806d">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV80L2ZyYWc6MTFjN2Y0ODEyOWZhNDdmNzhkNDlhNGE5MjFiODMzNmEvdGFibGU6YTZiN2MzY2I1ODQ5NGIwZmI4MTk3MDc1ZTVhM2QzOTIvdGFibGVyYW5nZTphNmI3YzNjYjU4NDk0YjBmYjgxOTcwNzVlNWEzZDM5Ml8xLTEtMS0xLTM1NTE3_164f8daf-2a23-4e10-89d9-da56fba9699a">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20220804.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-04</xbrli:startDate><xbrli:endDate>2022-08-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i79ad90fd7c4540fa9a3ef29aa494d30e_1"></div><div style="min-height:21.6pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzQw_11c45e08-0135-4afb-acea-1e5b0066c6cd">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18yNjI_52a9d51b-fdca-47dc-9f71-92968ec5180f">August 4, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzM2_885684a1-1987-409b-91a6-b6327dc807b7">Arvinas, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTAtMS0xLTM1NTE3_afd643a9-49f9-41f4-a90f-730a66bda742">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTEtMS0xLTM1NTE3_48e45354-ce17-40d6-ae92-58d3e6930714">001-38672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTItMS0xLTM1NTE3_93d3826f-fa28-406b-b3b3-527ef638bedb">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfNQ_bb8c7749-ecfb-4512-b370-cf0086fd4d5e">5 Science Park</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfOA_548868f9-3a2c-4d0c-acd9-31c34fa782c4">395 Winchester Ave.</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfMTE_1ebf31c5-bdea-4125-9fdd-1e5e3c4a07e1">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfMTU_e9df5f5c-5e35-4c41-9b26-927406720325">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTEtMS0xLTM1NTE3_1c681172-d885-4993-971a-d6995cc81749">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzMw_0df92544-6f9c-499f-98fc-459d585eda6d">203</ix:nonNumeric>) <ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzMx_57017e7d-2af3-43f0-a721-c27852c17340">535-1456</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:1pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl8wLTAtMS0xLTM1NTE3_1cfc32e3-4797-4941-99a5-f9355c51b391">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl8yLTAtMS0xLTM1NTE3_4e0f93ac-0e14-4b9a-8178-f9bc60ecab64">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl80LTAtMS0xLTM1NTE3_e81b6117-0fd0-4e86-b994-1c572bd8f09f">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl82LTAtMS0xLTM1NTE3_d286b20c-f9ba-4090-864f-84246ebb8a57">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:38.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTAtMS0xLTM1NTE3_2ac0ffcc-2762-48ff-a577-8a8b543d3c79">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTItMS0xLTM1NTE3_4a83e12c-7897-47ba-b8a2-95aaa14a86a2">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">The <ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTQtMS0xLTM1NTE3L3RleHRyZWdpb246NTRiNjkwNzBhNWNkNDIxNDk4YWVhNThiZTFlMTgwOTNfOA_a5a18463-36ca-4ee4-ae01-964b59748967">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzM5_5c670256-0496-4930-a06a-0a9fdcf02225">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i79ad90fd7c4540fa9a3ef29aa494d30e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, Arvinas, Inc. announced its financial results for the quarter ended June&#160;30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i79ad90fd7c4540fa9a3ef29aa494d30e_10"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="arvn-20220804xexx991.htm">Press Release issued by the Registrant on August 4, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i79ad90fd7c4540fa9a3ef29aa494d30e_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ARVINAS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sean Cassidy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sean Cassidy</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arvn-20220804xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i66a1a949d7044cedab1dea0c52310698_1"></div><div style="min-height:90pt;width:100%"><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEW HAVEN, Conn. &#8211; August 4, 2022</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Arvinas, Inc. (Nasdaq&#58; ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;This is an exciting time at Arvinas as we remain on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year, have a clear development pathway for bavdegalutamide in molecularly defined metastatic castration-resistant prostate cancer, and are preparing to initiate our Phase 2 trial with ARV-766 by end of year.&#8221; said John Houston, Ph.D., president and chief executive officer at Arvinas. &#8220;In June, we had a collaborative meeting with the U.S. Food and Drug Administration to gain alignment on the registrational trial design for bavdegalutamide. Based on our goal of advancing this important potential treatment for prostate cancer as quickly as possible, the promising clinical data we&#8217;ve seen to date, and a productive meeting with the Agency, we have decided to move directly into a pivotal Phase 3 trial. If successful, we think this approach may lead to the fastest potential path to availability for patients in need, both inside and outside the United States, and who are most likely to benefit from this innovative therapy.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Highlights and Recent Developments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Arvinas met with the U.S. Food and Drug Administration (FDA) to discuss the potential for an accelerated approach for bavdegalutamide based on a single arm Phase 2 trial and a confirmatory Phase 3 trial for full approval. FDA provided advice on the proposed registrational trial design, including patient eligibility, study design, and follow-up expectations.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">After considering multiple factors, including input provided by the FDA, Arvinas believes a randomized, pivotal Phase 3 trial provides the best opportunity to enable simultaneous global regulatory submissions.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">The planned Phase 3 trial will evaluate the safety and efficacy of bavdegalutamide in patients with AR T878X&#47;875Y tumor mutations and is expected to initiate in 2H 2023.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Final dose selection for the planned Phase 3 trial will be based on data from additional patients enrolled in the ongoing Phase 1&#47;2 trial, which the company expects will confirm 400 mg as the Phase 3 dose. This further dose exploration will run concurrently with the company seeking regulatory guidance on final Phase 3 design.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Arvinas finalized an agreement with Foundation Medicine to develop the FoundationOne&#174;Liquid CDx as a companion diagnostic for use with bavdegalutamide.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Arvinas launched the Global Early Career Researcher Award, which seeks to recognize the efforts of up-and-coming researchers bringing innovation, new approaches, and creative thinking to advance the field of targeted protein degradation. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Arvinas appointed John Northcott to newly created position of Chief Commercial Officer, effective August 1, 2022.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Anticipated Upcoming Milestones and Expectations</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARV-471</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Present data from the VERITAC Phase 2 expansion trial (200 mg and 500 mg) (4Q 2022)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Initiate two Phase 3 trials in patients with metastatic breast cancer (as monotherapy and in combination) (2H 2022)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Initiate a Phase 1b combination trial with cyclin dependent kinase (CDK) inhibitors or other targeted therapies (2H 2022)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Initiate a Phase 1b combination trial with everolimus (2H 2022)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Initiate a Phase 2 neoadjuvant trial in patients with early breast cancer (2H 2022)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Present safety data from the Phase 1b combination trial with palbociclib at a medical conference (1H 2023)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bavdegalutamide (ARV-110)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Initiate a Phase 3 trial in metastatic castration-resistant prostate cancer, or mCRPC, for patients with AR T878&#47;H875 tumor mutations (2H 2023)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARV-766</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">Share Phase 1 dose escalation trial data in mCRPC (2H 2022) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">Initiate Phase 2 expansion trial in mCRPC (2H 2022)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Guidance</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on its current operating plane, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2022 is sufficient to fund planned operating expenses and capital expenditure requirements multiple years beyond 2024.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Quarter Financial Results</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Marketable Securities Position&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;As of June&#160;30, 2022, cash, cash equivalents, restricted cash and marketable securities were $1,347.7 million as compared with $1,507.1 million as of December&#160;31, 2021. The decrease in cash, cash equivalents, restricted cash and marketable securities of $159.4 million for the first six months of 2022 was primarily related to cash used in operating activities of $141.5 million (net of $6.5 million received from two collaborators), unrealized loss on marketable securities of $17.4 million, and the purchase of lab equipment and leasehold improvements of&#160;$3.5 million, partially offset by proceeds from the exercise of stock options of $3.0 million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Research and development expenses were $75.3&#160;million for the quarter ended June&#160;30, 2022, as compared with $43.0&#160;million for the quarter ended June&#160;30, 2021. The increase in research and development expenses of $32.3&#160;million for the quarter was primarily due to an increase in our continued investment in our platform and exploratory programs of $19.6&#160;million, as well as an increase in expenses related to our ER program of $14.1&#160;million, which is net of the cost sharing of&#160;ARV-471&#160;under the global Pfizer collaboration agreement to develop and commercialize&#160;ARV-471&#160;that was initiated in July 2021 (ARV-471 Collaboration Agreement), offset by a decrease in our AR program (which includes bavdegalutamide&#160;and&#160;ARV-766)&#160;of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.4&#160;million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;General and administrative expenses were </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.3&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2022, as compared with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.4&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2021. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.9&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was primarily due to an increase in personnel and facility related costs of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.9&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and insurance, taxes and professional fees of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.9&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Revenues were </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.3&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2022 as compared with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.5&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2021. Revenue is related to the&#160;ARV-471&#160;Collaboration Agreement, the license and rights to technology fees and research and development activities related to the collaboration and license agreement with Bayer that was initiated in&#160;July 2019, the collaboration and license agreement with Pfizer that was initiated in&#160;January 2018, and the amended and restated option, license and collaboration agreement with Genentech that was initiated in&#160;November 2017. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in revenues of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.8&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was primarily due to revenue from the&#160;ARV-471&#160;Collaboration Agreement.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Tax Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Income tax expense was </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2022, as compared with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">zero</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2021 due to taxable income projected for fiscal year 2022 primarily related to revenue recognized in 2022 for tax purposes from the ARV-471 Collaboration Agreement.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Net loss was </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70.0&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2022, as compared with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50.3&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2021. The increase in net loss for the quarter was primarily due to increased research and development expenses, general and administrative expenses, and income tax expense, partially offset by increased revenue.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About bavdegalutamide (ARV-110)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC&#174; protein degrader designed to selectively target and degrade the androgen receptor (AR). Bavdegalutamide is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bavdegalutamide has demonstrated activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About ARV-471</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARV-471 is an investigational orally bioavailable PROTAC&#174; protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+&#47;HER2- breast cancer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a CDK4&#47;6 inhibitor. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of ARV-471&#59; Arvinas and Pfizer will equally share worldwide development costs, commercialization expenses, and profits.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About ARV-766</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARV-766 is an investigational orally bioavailable PROTAC&#174; protein degrader designed to selectively target and degrade AR. In preclinical studies, ARV-766 degraded all resistance-driving point mutations of AR, including L702H, a mutation associated with treatment with abiraterone and other AR-pathway therapies.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARV-766 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer, and ARV-766 may also have applicability in other AR-driven diseases both in and outside oncology. ARV-766 has demonstrated activity in preclinical models of resistance to currently available AR-targeted therapies.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Arvinas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> protein degraders against validated and &#8220;undruggable&#8221; targets, the company has three clinical-stage programs&#58; bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer&#59; and ARV-471 for the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">treatment of patients with locally advanced or metastatic ER+&#47;HER2- breast cancer. For more information, visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.arvinas.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic benefits of ARV-471, bavdegalutamide, ARV-766 and our other product candidates, the future development and potential marketing approval and commercialization of ARV-471, bavdegalutamide, ARV-766 and our other product candidates, including the initiation of and timing of data from our clinical trials. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to&#58;, whether we and, as applicable, Pfizer, will be able to successfully conduct and complete clinical development of our product candidates, including whether we initiate and receive results from our clinical trials on our expected timelines or at all, obtain marketing approval for and commercialize ARV-471, bavdegalutamide, ARV-766 and our other product candidates on our current timelines or at all and other important factors discussed in the &#8220;Risk Factors&#8221; sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential benefits of the Pfizer collaboration and the potential advantages and therapeutic benefits of ARV-471, bavdegalutamide, ARV-766 and our other product candidates, the future development and potential marketing approval and commercialization of ARV-471, bavdegalutamide, ARV-766 and our other product candidates, including the initiation of and timing of data from our clinical trials. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to&#58; each party&#8217;s performance of its obligations under the Pfizer collaboration, whether we and, as applicable, Pfizer will be able to successfully conduct and complete clinical development, including whether we initiate and receive results from our clinical trials on our expected timelines or at all, obtain marketing approval for and commercialize ARV-471, bavdegalutamide, ARV-766 and our other product candidates on our current timelines or at all and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other important factors discussed in the &#8220;Risk Factors&#8221; sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">###</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investors&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeff Boyle</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">+1 (347) 247-5089 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeff.Boyle&#64;arvinas.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Kirsten Owens</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">+1 (203) 584-0307 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Kirsten.Owens&#64;arvinas.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i66a1a949d7044cedab1dea0c52310698_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arvinas, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">June 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">93.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">108.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,250.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,394.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other receivables</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">19.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,376.4&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,552.5&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right of use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total assets</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,407.0&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,581.6&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">42.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">194.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">206.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of operating lease liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">238.2&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">261.7&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">493.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">534.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">736.4&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">799.9&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#59; 53.2 and 53.0 shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">0.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(816.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(682.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,508.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,469.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(22.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">670.6&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">781.7&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,407.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,581.6&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i66a1a949d7044cedab1dea0c52310698_7"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-top:6pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arvinas, Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations (Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.3&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5.5&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55.5&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.1&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">75.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">43.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">139.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">77.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">24.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">44.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">99.6&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">57.4&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">183.7&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">104.6&#160;</font></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(68.3)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(51.9)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(128.2)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(93.5)</font></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest and other income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(66.6)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(50.3)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(125.5)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(91.3)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3.4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(7.9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(70.0)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(50.3)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(133.4)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(91.3)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss per common share, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.32)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.03)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2.51)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1.87)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted average common shares outstanding, basic and diluted</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.2&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">48.9&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.1&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">48.7&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>arvn-20220804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45999cf6-02eb-416a-9d0a-8f65ab11b7f5,g:111baa97-bb12-408d-a1db-041cb338d317-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20220804" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20220804">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20220804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arvinas.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>arvn-20220804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45999cf6-02eb-416a-9d0a-8f65ab11b7f5,g:111baa97-bb12-408d-a1db-041cb338d317-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_786bf986-49b0-459e-bdcf-1910f0fa3379_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_690dbba0-1a9d-4e5f-bf39-a337324d5244_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a90aa32f-58a8-4719-84aa-d6ef727f97ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_836168f8-f9ce-425c-8bd9-5a0c1bcb1923_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7e5b1ad1-b3fb-414d-bd37-f1eef7b94f9d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ee976f5c-2749-45ed-a3bc-7cba80a6710e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6b122cf2-2194-4255-8cf6-8b21f7d4d3d4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_6102cc43-2139-4372-8c8b-6309f265cc37_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_939e1587-ef31-4611-8bc5-6217910d1f5d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_205ed6ca-f0c8-495d-846b-bdbe63b38f91_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9ff7838f-f342-485a-9123-efbb028983df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_eca95624-f37e-4f90-a62e-87f6f96421f9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c90e1cc6-4ea7-46cd-8b48-33167f5d9b3c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_06372514-102f-458f-afae-1f38ec378e15_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b5ec3cf0-cecb-4d64-b18d-37cdb3057065_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4d11c2b1-32e2-4a48-a104-c0d3493ea667_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fa441a64-1ad8-48c8-8eed-25da098f9ac8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_949541c2-8aa5-4525-bd98-5840076c2fcb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0607876e-5c3b-4b0c-8542-3f43468eb443_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_036cdab7-4ecb-494f-b054-4c910b11702a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ffa15223-ac4d-466f-98be-c271eef6193f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c3c3b29d-3eaf-4db9-b7ef-3541c52bf995_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dba66b80-b6da-477a-b56f-cc477af4e487_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>arvn-20220804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45999cf6-02eb-416a-9d0a-8f65ab11b7f5,g:111baa97-bb12-408d-a1db-041cb338d317-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/Cover" xlink:type="simple" xlink:href="arvn-20220804.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6d72eb7b-34bb-4a34-8e76-0961a3f7c119" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_DocumentType_6d72eb7b-34bb-4a34-8e76-0961a3f7c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f978ffa5-033a-4abc-b2a4-42dd0d7037f5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_DocumentPeriodEndDate_f978ffa5-033a-4abc-b2a4-42dd0d7037f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_adcda343-50a9-4710-8fbc-5f2384bde550" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityRegistrantName_adcda343-50a9-4710-8fbc-5f2384bde550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a6aa4269-c687-42fe-aae0-273b84bb89b0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a6aa4269-c687-42fe-aae0-273b84bb89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e138fe4e-f46e-4da6-8e15-0ada52839c22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityFileNumber_e138fe4e-f46e-4da6-8e15-0ada52839c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e61575bf-9904-4115-8f6f-d2630a06eadb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityTaxIdentificationNumber_e61575bf-9904-4115-8f6f-d2630a06eadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e501f94d-fe58-4258-ac25-5a75aeced2ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityAddressAddressLine1_e501f94d-fe58-4258-ac25-5a75aeced2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_3f71eb1a-7173-4a58-a827-29e6e75c7dec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityAddressAddressLine2_3f71eb1a-7173-4a58-a827-29e6e75c7dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3965a856-3599-4fef-9e70-45f067f59ded" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityAddressCityOrTown_3965a856-3599-4fef-9e70-45f067f59ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_49c97677-4629-42ff-9b75-32cb37c073fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityAddressStateOrProvince_49c97677-4629-42ff-9b75-32cb37c073fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bfe854f4-e9f7-4a74-8abf-e2af1f2e3c65" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityAddressPostalZipCode_bfe854f4-e9f7-4a74-8abf-e2af1f2e3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5cc6b6d1-9c50-43f5-8a41-30d095ec436a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_CityAreaCode_5cc6b6d1-9c50-43f5-8a41-30d095ec436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fc261664-6803-4f08-9a99-85c9c7c444af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_LocalPhoneNumber_fc261664-6803-4f08-9a99-85c9c7c444af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8e5750ea-7468-4915-b9cc-5d8f50289d9e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_WrittenCommunications_8e5750ea-7468-4915-b9cc-5d8f50289d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_aa58130f-d872-4a4d-bfe8-ea9844706bb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_SolicitingMaterial_aa58130f-d872-4a4d-bfe8-ea9844706bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_fa874306-2368-4538-a2e7-a69536fcc489" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_PreCommencementTenderOffer_fa874306-2368-4538-a2e7-a69536fcc489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7cd67c0c-10a8-42c9-907b-01d449b37575" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7cd67c0c-10a8-42c9-907b-01d449b37575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ce2c98ef-a0da-4931-baba-89c36f2aef99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_Security12bTitle_ce2c98ef-a0da-4931-baba-89c36f2aef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0fb7f3d3-e830-43da-9e9d-00e2ce089b0f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_TradingSymbol_0fb7f3d3-e830-43da-9e9d-00e2ce089b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2ee1a62f-d7f1-411f-9748-164711d93b13" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_SecurityExchangeName_2ee1a62f-d7f1-411f-9748-164711d93b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bc3b1dae-4222-4ed9-a56c-f2cadf5c89b0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityEmergingGrowthCompany_bc3b1dae-4222-4ed9-a56c-f2cadf5c89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_81bf57c3-448e-4acb-bfdf-50776268e7c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_EntityCentralIndexKey_81bf57c3-448e-4acb-bfdf-50776268e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c088ed6c-37bd-465d-84e9-1faefff66b85" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_10005bcc-1684-4c70-899d-3e415d08b03a" xlink:to="loc_dei_AmendmentFlag_c088ed6c-37bd-465d-84e9-1faefff66b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %M X # 2(  A$! Q$!_\0
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MEJD<!\N@"2.Y6X.U>U3 8&*S=+\T2G*]ZTATYH **** "BBB@ HHHH ****
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M;KQGTI(]+T?PZ?M+OM[]*0&TU*875NVY?6@"<(8$$I/49JQ#<+)'M/-07UQ
MD(4MT&*FT]8Y(MRT 30QJ#D#WJ2JFH-/&/W"YJ:S9VBS(.: ):*** "BBB@
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MM_LEOH94XQE=.8?TK],_^":O[6D?[6_PC_X3-("F84;!B*]?K7!V_P#P0?\
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MRFDWMZT]";CZ*:C$]:=0-.X4444#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ([D9B(KR_P",_B$>'[1VWX^3^E>H7;!8"37S
MI^U]XB&GV#^7)C]W7S'%N/\ J62U&NQ]#PME\,=G5)274^1OCUXV;4?$4J!R
M<YZ5Y?!.5<L2>2:VO'%[)J7B-G9LCGG\:R-1A%N!@8K^(LQS">(Q]1ONS^TL
M%@H8; TTET0VWA6:YR<58OH1 0,5!ICCSP6_*K.MOF1=OJ*\S KFQ1Z6+JR6
M&21#<1#[-O JC'*48#WJ](^;4*.M4A$=P.*WJ4ES-F%*J[(M@&6, U0O+9HY
MPP'0UIP;%4$]*9<B)SDC-13_ '<KG2U[1%CP[XADT^4?,W!K[._9/^(Q.DQ6
M[2_>517Q/;VPW95>M>_?LYZ]<6%Y:VXDP"0,5^D^'6;_ %//$[]+'YSXBY0L
M7D;5NMS]!M'NQ>6$4F0<KFK.0I%<[\/KQ[G2+5B<YC%;<SD2[>U?UQ@,0ZE!
M3[G\E8C#J%9T^Q8=@W4T]7"(3G&*ABR1DU1\2ZS;Z;ICRLV,>]=F)JQA1<WT
M.6E3<ZRIHS/'/CFW\.1EFD3IWQ7BOQ$^.JQPN$N .O2N?_:&^*,[;X[*YZ<=
M:\ U[QGJ5ZS"2;.?>OP7BOC;$4,9.C2>B/W/A'@:C6PT:]9*[.M\7?'&ZFE;
M9<R?>[$UC6/Q?O/M&\W,O_?1KBGD-TV9#GFI$A2,;A7YA6XMS*56_,S]2I\*
M9="GR\I[7X.^.LEF%W7#?B:]9^'OQ^CU.Y6T,X[=:^.9+Z]A.+=JV? ?B[6M
M*U;SYIL)D=Z^DR7C3'QQ,(REI<^>SG@K+ZF'G*,=;'Z,>%O$T6IP;A(IR/6M
MS =0W'-?-OP8^*1O(HUDN.2!WKZ!\/ZG%?V,;ALY%?T1DF<0QM-:G\\YYDT\
MOK:HO@ "JURA?( JU(IS1'"CMAJ^@=^:YX49\JL1VJE(3GTIJR$M5AD 7@5#
M))#!DO6O-"*O(X:D:M6?NDJ,#U%/#@>E9%UXDT^U)#O@_6J,_CK2X^/-Z'UK
MBJX_#0=FSOHX'$S6B9TK.,<D8]*KRC<<9K$M?&VF3/M\W]:U[75K*Y \MLYI
MT\?AI[,FM@<3#=%F(X&TBGTL?ENN5H9<<CI77&:EL<_(XC@5*X)I F1UJ*20
M*.M$,A<9S0Z:>I2JVT'DXZT Y&:?@$9(J-FP0!67)=V-G-)7%HI05QR*4LF.
ME'LY"]I$;133,@ZFG)+&:'3G87M("QK@]:?34=6Z"G544TM0OS:A1115 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)J*K0:@D_*XYJR#D9K9IK<SC4C/8****184444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 131[FH,:JN1Z4LK8;I1+)L0,:F"]X*FL#
M-OK?S+@-CO5O8&@"@=J:2)/F S2P3+OVGUX%157/*Q%%<BN0ZA<1Z=ITMS*V
MT(N2:^<?VC?VL]&^&]E)(NL^6R*<_-BO8?CIXQB\.^ M3NBX4QP$YS7X=?\
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M*@'F$5X/^U_\:;#X::%.\TX3-L>K8ZBO9M;U=;'2WNI'VJHY8FOS!_X+1?M
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M:Q'LW>YS/CC1=(\0:--IT]A')YG4$5Y%H?[+/@Y]2DNKCPG;-NE+9,?O7O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140115636129440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arvinas, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>arvn-20220804_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arvn-20220804.xsd" xlink:type="simple"/>
    <context id="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV80L2ZyYWc6MTFjN2Y0ODEyOWZhNDdmNzhkNDlhNGE5MjFiODMzNmEvdGFibGU6YTZiN2MzY2I1ODQ5NGIwZmI4MTk3MDc1ZTVhM2QzOTIvdGFibGVyYW5nZTphNmI3YzNjYjU4NDk0YjBmYjgxOTcwNzVlNWEzZDM5Ml8wLTEtMS0xLTM1NTE3_26bb8f1b-8be1-4149-9f27-3e52fcb8806d">0001655759</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV80L2ZyYWc6MTFjN2Y0ODEyOWZhNDdmNzhkNDlhNGE5MjFiODMzNmEvdGFibGU6YTZiN2MzY2I1ODQ5NGIwZmI4MTk3MDc1ZTVhM2QzOTIvdGFibGVyYW5nZTphNmI3YzNjYjU4NDk0YjBmYjgxOTcwNzVlNWEzZDM5Ml8xLTEtMS0xLTM1NTE3_164f8daf-2a23-4e10-89d9-da56fba9699a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzQw_11c45e08-0135-4afb-acea-1e5b0066c6cd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18yNjI_52a9d51b-fdca-47dc-9f71-92968ec5180f">2022-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzM2_885684a1-1987-409b-91a6-b6327dc807b7">Arvinas, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTAtMS0xLTM1NTE3_afd643a9-49f9-41f4-a90f-730a66bda742">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTEtMS0xLTM1NTE3_48e45354-ce17-40d6-ae92-58d3e6930714">001-38672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YmQ4MzkyYmFmZDkyNDcxNDlhMTg4ODY5NmQ4MzAyYWIvdGFibGVyYW5nZTpiZDgzOTJiYWZkOTI0NzE0OWExODg4Njk2ZDgzMDJhYl8wLTItMS0xLTM1NTE3_93d3826f-fa28-406b-b3b3-527ef638bedb">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfNQ_bb8c7749-ecfb-4512-b370-cf0086fd4d5e">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfOA_548868f9-3a2c-4d0c-acd9-31c34fa782c4">395 Winchester Ave.</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfMTE_1ebf31c5-bdea-4125-9fdd-1e5e3c4a07e1">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTAtMS0xLTM1NTE3L3RleHRyZWdpb246NDc1NmZlYTUwZDAzNDZiM2I0ZTk4YjQ5MTZhYWIyNzBfMTU_e9df5f5c-5e35-4c41-9b26-927406720325">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6OTgxNzdjNGU5MzJlNDVjNjg4NzQ5ZjNjZmY0ZDBkOTcvdGFibGVyYW5nZTo5ODE3N2M0ZTkzMmU0NWM2ODg3NDlmM2NmZjRkMGQ5N18wLTEtMS0xLTM1NTE3_1c681172-d885-4993-971a-d6995cc81749">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzMw_0df92544-6f9c-499f-98fc-459d585eda6d">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzMx_57017e7d-2af3-43f0-a721-c27852c17340">535-1456</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl8wLTAtMS0xLTM1NTE3_1cfc32e3-4797-4941-99a5-f9355c51b391">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl8yLTAtMS0xLTM1NTE3_4e0f93ac-0e14-4b9a-8178-f9bc60ecab64">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl80LTAtMS0xLTM1NTE3_e81b6117-0fd0-4e86-b994-1c572bd8f09f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6YWNkN2M0ZjIzM2I0NGNlZDg0MWIzZTBkOGQwOTA0N2YvdGFibGVyYW5nZTphY2Q3YzRmMjMzYjQ0Y2VkODQxYjNlMGQ4ZDA5MDQ3Zl82LTAtMS0xLTM1NTE3_d286b20c-f9ba-4090-864f-84246ebb8a57">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTAtMS0xLTM1NTE3_2ac0ffcc-2762-48ff-a577-8a8b543d3c79">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTItMS0xLTM1NTE3_4a83e12c-7897-47ba-b8a2-95aaa14a86a2">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGFibGU6M2QyMDYzYjJlZTljNDkzNjgwYzY1MDY3NDEyOWRlNWMvdGFibGVyYW5nZTozZDIwNjNiMmVlOWM0OTM2ODBjNjUwNjc0MTI5ZGU1Y18xLTQtMS0xLTM1NTE3L3RleHRyZWdpb246NTRiNjkwNzBhNWNkNDIxNDk4YWVhNThiZTFlMTgwOTNfOA_a5a18463-36ca-4ee4-ae01-964b59748967">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic803203aca6d47cf921d79e896af21e1_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5YWQ5MGZkN2M0NTQwZmE5YTNlZjI5YWE0OTRkMzBlL3NlYzo3OWFkOTBmZDdjNDU0MGZhOWEzZWYyOWFhNDk0ZDMwZV8xL2ZyYWc6NDQ4ZGY2NDBiMDE4NGRlMjkwZmM0YjA1NDY5OTVjNTMvdGV4dHJlZ2lvbjo0NDhkZjY0MGIwMTg0ZGUyOTBmYzRiMDU0Njk5NWM1M18xMzM5_5c670256-0496-4930-a06a-0a9fdcf02225">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSN*'AI%9<?Y=2@.GZ>)VPR@8AGT!OE]):=X;]DA=_B,R_!M02P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ A($%50=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "$@055=9\Z=>\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "$@055F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (2!
M!55;B2?_6@0  !T1   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "$@055GZ ;\+$"  #B#   #0
M        @ &>#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (2!!567BKL<
MP    !,"   +              "  7H/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( (2!!56JQ"(6,P$  "("   /              "  6,0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "$@055)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "$@05599!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arvn-20220804.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="arvn-20220804.htm">arvn-20220804.htm</File>
    <File>arvn-20220804.xsd</File>
    <File>arvn-20220804_lab.xml</File>
    <File>arvn-20220804_pre.xml</File>
    <File>arvn-20220804xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arvn-20220804.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "arvn-20220804.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20220804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20220804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arvn-20220804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20220804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220804.htm",
      "contextRef": "ic803203aca6d47cf921d79e896af21e1_D20220804-20220804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.arvinas.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20220804.htm",
      "contextRef": "ic803203aca6d47cf921d79e896af21e1_D20220804-20220804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001655759-22-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-22-000029-xbrl.zip
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M_3SQ6=JO$DGZOU*6<^M+,J+ 4TY<@?+YY[R:B\JVOJ34"?BB3B>*@4#L1D%
M1PFO+CY\7LBF7)KBK-#G(8U/@0@G2M-H6-6  E#W4M^E ::!?QI6Q4 4R9?$
ME:6<P!0&(F6+EHOD<I942=G--,LL6]+MR5*97*15LKKC189BE)116LK*0:_$
M8'PM*:5K'2^Z CD1B\9B8'X#:C^/*&-^>%J5$,GJN&RDDHW$JMG)QR:-1E4H
M\SD;B7Q07.!1'I?RR5ED!Y*BN"H:$^UYP$, Q4,_F%7_T_&'@ 0VGZ!V-*3A
M?S83T&) O8I]+\^8^'->)2:TDGV=Y+TUH)YLKHK>$UF,W9'=Z-1KZ+"SW:D?
M+O/$%>)?"[6']9VC=J/3J!^B;;N&ZG_M_+X-R(]V6LUFX_"PT;)?L OR6ETX
MWC[\O6'O=5KV)JJ5=\I@OVBJ]11D;\<^#6XC5KI&K+J2V),;_VXE] I_:Z^(
MOW=;[29Z0@5J8;;FZO]+JDG3A9IDUP[4WEY7MFO?_&:MKMI[[: Y.(.VFJ#"
M;!.[UM5:G1\#N],$E>>'RG[_(^C)P;DSB"2[UC_K#;K03F/2[)Q*O;VCF6B_
M.V]#74>2/3C3[.,F:1)SVIP?3$X( 1G%A3PDBH95ZCF8NIQBPC5'DG3=U5U0
M,4S\YTTEYQUQ?%;Y:T$8@,AVW>Z@=OU[J]UY]8#X?1PG8QJF*(W0(7>%)8Z(
M@J(8$6V#?7KU]$<>2OM<D#Z._=2'BNM3MP\Z.D?;;HH@F5B*^N:X2*BT@O@V
M'T5QBC86WSD%I98G*>+GPEL79\F<?:H^!\I^SU3K>JYP+YNK#'[!0VBS+XJ!
MF37#,Z 5\_"?!<LS>] XT61J,8TXV&,NQ:K!7&QY!L&6;.DF=S5B2EYI:WM\
M.H:)5#<S'^J[!NAG44ED=:V5]>0NNS8_]1/AVTQM2/EGL3]H)4WYQ#0UW50I
MP<0R#:Q*EH,M0G7LZ(H,B\&4#,< _H_/_9 FFZ@1NN7G8/\U ?KZ0EC-1AOU
M*07Y(B9?X')\,>F()B@9<5<X0ACR0^2G"0*)!# =/XDX?7UJUYOQ82AR65:4
MM7P8KZ5:]3X>E]O<*PL'BCR:HI7ND!NC'HV>?YT1]3G@&M GBD&+RC:A#E/0
M8W:B<9C&LYV(+2LY8@]->"93/HJC<U'/&]5N"M_\\$!MSL]FW>$NM'4VLVON
M5/CR >+5%N2WL_1MJ/^&;][OU4[GK<X??O>X![0V)'L._3BN3UNU4Q7$@2S2
MF[4_^MUL0V9[V3=//::K"K6P:GGPAW@JII;D84.1J*X[C!JJ#!HP#^B$QOQ6
MR5"L@0_VOI.]=_V 0^T. /,'J_Z<5:]M(ZDF5S5%4['+B=!DF(XIMV2LF4SA
MNJ5(!E'%5@C!BJD;MROQ'[RZ#J]VZ+11["&Y&1Q_,.[:C-M89EQ+88HIZQYP
M@FP"X^H.=A1'P9IL<$]73(<SI[2E&EC6=!V4P#LY]PUH$S]U1V<*XD8FWX5S
M*TK[/$:#<>PGS,^\7MFV'&CR_E5]X-,;6<%K=G\G&@[])%GT5L@&E*^Q=];1
M1OL0U8>C()KQ..OJ,JX@.RI_NLGB:^T>OGFC1UU_X_:)JGTXG@3<NS$X^;B4
M7IN7@&C/(3*W&8MYDA3_[0,!Y V+RU;G=&K/H8V](ZTY_R.P:Y ^ '$W/]!Z
M\*DW[$([WX 6]YJXC+16K:Z(_O0Z9_/F\$BRCYLRB$H%Q.VP*=O#W@#ZM'>@
MV>2F2;*OM /^>WO6.V8C1U:!=I= B:#;.9KT:MMSN];SFW)#U*UV!S!VG5X?
M1/;,GG_S[(,3QS%=PU MS%W/P:I&9!"VAH1=3Y),W6,JTWAI2T.'KB]">M!W
M&I^])8?72[&R_,'*S\K*K>T3335-W02S7*&RBU4FN9BZ#+X25U$]:IBR"P:/
M8FGH&!2E/D^ (='V.5_?@;LL[)XG&.=U<?@.?&S%G6CREKU';Y&_FYWZ">&.
M!\RL88=QBE4B:]CR&!,1$UQQ52H9($&W!$?]3L]Y>)VM-Y]RGW6)2S)3I15_
MCZ-S/XOE?[^>R+?)2T<GW&*>YFDN!M;1L.JJ!%N.K&-+-L#B-H 39*VTM1.%
MH0BL<,?IW2#YF*;7A5+\+AU%Q1+Y'L$:"'K^*'?5?_#_3_G_>I2\JYN$&#)F
MI@D,;%D*M@Q",=,M2W-=DX!26]J2=(V0=^\@RCAWH^ LL:4[B@%W_1$-$)]R
M6+S^N=CI]7R7)^_&6Y)W&E80$DOHL5TB+[$O?QE]\>_?3)D8GQ.4\H"/^E'(
M49CYNC:%CR\8B]E!-.849H_Q*MIX0M@2*M\V-/5F@>J7(D(F)Q*#$=-4%>N>
MY0J@\;!E>O!)LYAF:IQ1<08+!O@ZS'QZ2GUK/X+5]UUPQAO>:/BEF9F>:(9$
M#&XP+%-/P:KB29@:,L&N;)B:[!)#4:72E@;Z#5$U_;Y6WO/%HZ^'#G:4(CH:
M!0"[ &LOYW-9+WI^8Q=4?K"O[2S(*$;%UT)& 8QY:"<+=67H4-@(:)\F:1$R
M^KY"C;3LG,_3<LQJ>G?ZW#W+0HR!;^((E *Q@^1$4^3P()J(.1")8FJ0B?]$
MGA\(N>(G(&12'C*8FS1"B3\<!RD->31.@AE*:.HGWBPK612(')B1?'.B"&F^
M$E(VAGIB1,/9(LV+ FA<E!,&H"]V=!(08,5(/M$X9356?5"Y?7>-D4LX?V*"
M[FP>[?&0QZ"]-4(8Q7$>V;Y=ELOYQ'VJWL-#=4W9>4N[/7+9LAY_L\=2RR9Y
MB<V>>RG)QU"QJ#QY,"=)3QPQ?!S[*:"$V)<=A\7F9/)*#X+_6B#$L9W1!'3,
MA4O%W@.::J=2\[@Q[W7 M-T[F+0ZVY(M=V\<!._*!PKH+\/FH#GO#@ZDKOSC
MK%4[F'8'=@"FK=JK;6O-VH'26Q5L1ES/560.JHUA&:!Y"A^-137L68JFN1IQ
M%(N4MJ+'C=RY<YORF<$P8^&"SZ ;5QD-C:X<_FF/ =!462N$S;5#->(LS08Q
MT,YN&\F*5(:,*ZS%>YWQ77F*]QY9/X#E#F YC$!(P]2%ITW05X3:]H$J#T:5
MV0U44;D$ $)=+'&B8M6Q*#:)80*J.*XN<; N=/7]H\HEDZ%AP64W(86H%!/Y
M"JHLG<^[P!05=(8LYSJPHGW RLO RO>8"UU%1#%DQZZ%@1.W/$_X3C[@Y8'P
M(MV %VX21R?$P)+')*QR4\>.9:F8N)HA.\ST),M[__ "S(;=*]SV4^V%J S+
M&\ZG]< FS_L!-V\';AI),N;Q!^@\!NC(-T"'R:;NR)(KE!@J3FU*V-15#YNJ
MK.K<<4RJ&1^@<Q-T%([5#7<]T"GR/G"C[>6\H%<LP=PMR6/.EL;BXNZ(#( +
M-R7T_Z=NME<45&U995,U'W20U"R;DOD@-]O=::JD/[KSCAAE4W\KQ(J1)?*+
M''I]&AQ:;T^^(^XFS2_\</O(#6B2W -H[Z&,_$*0_0M$<OY\\$0@9R>FHF^O
M*01U/<(/9T,G"C:23_<.#/N'S[A=7,.0K19>B-^W-_\@/R=]'[IP*617<,)/
M<*X0D\55ARB) I\MWYOXSSYK6N@R,R([&<J^85NA*1_,FK4NZ/I_!+U. &V=
MS>W!Z01^(?"[8F=7];8#^[AY/7!PWJLU)O; ]IO#'T'KN E]$(&#WP;VX A^
M=Z5FIZ'U]HY(EXCK=:_9"C)U)<]S72P;NHQ5T_,P6 <&-JGI:*K"%->P1.3K
M<!@)UHG<LTTTHC$ZI\&8H_\5NYD$C<0ML_U?.^*_!NY]K(>[UT,A+7/9\[$8
MUE@,U\Y:J]14.)%=;)ABB]$ ZQF,91E;&J640*I.Y=+6=ON'_0H9_78OTBL[
M@Y9IQ6!3/H-D6-CO^?U=U\]="/7BS1^Y>+[%<G#WD8M.V[>!5GO^K6\+SU>M
M,05:U.[QC[[=Z?N]SF[0[)Q.6AU;'$^C&B6FJBM8T<7->IRKF'*)8$M7'<TR
M5)AI0VB#":-_7U]LZ%#((=2D\1E/T?[^SFVJU;HQSR_DBVF$3'BC.')FR,VB
MTX"N,U <>7:GP;70,3]!0"*'(3@5^W2G<31)^\*I-1+A9#1!C'O01'9361X"
M(&GHYJ6:EW=I*FCCW[\1W?B<A0$L,OO9'6<C<<>9B%3,/6.R@^45=:VZH/.B
M4N$ENRQWI=KRZXX3K-\RPO<,@?MUG_SS7'*XZ.Y>UMN=O+/ORQW_2X'5VHGF
MZH8D:SJ65$O'JJ5(F$HZQ1*U/.9Z,++B<-CM[O17"C[>'7 B#E:LQ";_1D1K
M'Y"'!]P53TV%4>9!'B<\RP6,6L3-BO>!_,RKG#_J(-@K:RN8B<:S)ZK$&@NA
M;Y 2\W,_@7* 9S1T13 "=5UQEYO(+%Y$8C1F21XQRVYS7RL;],)]?16HRB^T
MDJ-[,,2;"4I]6V]'++_J,8IRGJS&/*#B4-B-=SXN"<DHD"Z+4 >4\G%ZL\C/
MG@:Y[PLE1FE1IA]?6A*G'#LQIV>8>B!1JS28T%E2JMSVC(FJ/>P1DVNF"Q8F
M1M60%W8'8 38$%4L?GFA8R"-E ^17)9DH71(GV_^;?-D'*39,< 68$^Q]P<(
M@G8OP&4G K 3"6MI)OJ+078K1/E5TWG7BONF-]'2_;O0MQ"@TA6*(/3[$D+C
M8B0$] I,_'N<W62+<HC^8QSRO%I%RNLM(V&D>>,@0-D#1064CK)3E;!D. 68
M]\5&?J9RNL7A:.'Y%'">';0H2,FV7T$#],9QZ"=]*$"%\MCW'3]%EE4F K@S
M'7%G',<B<W%;.E2V.(^QUMR0Y^#$U9,C!LL/+Q[!$T.2]>CB/,G&Y5G%JUW_
M)#QG,,9"=CH<E'@8+8;$D4<9R/4#SK+/Y',V<2#I (-XQL\7DLY<4S7?%,-.
MA_F$;X@"13-7,Q>M?=J\N%QM K(8)6-G .WE$\51X%/'#_*FLL9IBI*<GDWH
M2EQTRK_:I\O[V. +J!47+V.)L1+2OSA <VO8<F&V7.U&1N5U";\I-@[X*+O
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MBUZ)(EUQ(C:#_\ V#;;^'U!+ P04    " "$@055V:O1!6D"  !K!P  $0
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MN\CS6M82)2U1PK!$^?>NP68#X!\(;]'$>@!P5;F?#H5Q%Z>?#@;WW,P/ZOB
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M='<6M*W?W8'N(GZRW?UQN;Q1^78+)80^$H)@HV=LG!9'R.@YYB#$/M4H#(3
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M,WYFCMZ^V+R2K'Y#_^V+_P-02P,$%     @ A($%5;G^X7K1!@  ]#(  !4
M  !A<G9N+3(P,C(P.# T7W!R92YX;6S5FUEOVT@2Q]_S*;2:UVVK[\.(/?!Z
MDH6QGHF1>)#!O@A]5-M$)-(@Z>O;;Y&V)SYW.:869EYDB6JRNO[U8W=547[_
M\]5Z-;N NBFJ<F?.MNA\!F6L4E&>[,Q_/_Y([/SGW7?OWO^-D#_^\?EP]DL5
MS]=0MK/]&GP+:799M*>SKPF:;[-<5^O9UZK^5EQX0G;[D_:KL^NZ.#EM9YQR
M_OC;>ELJYUS,FE .@4BF/7&)>F*S5CXP%DQ6?S_99OC.>V=("(P326TBGJ5
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M59&+F[+CSA'-E%$A$^<H*L+0!RR\,DE<"^JI!I_"!E!XP?P@+O34N=B$MI.
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M0KWG$"^VM4O$'+YN_Q*((9?NI"GIY."G,Q4E?PT:OVHE;9$+E9\KQ-CMC:5
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M#W$P2&W86Y3@*I":;Z3:U=-*M<#J@6&U7:LT<HG4O2LPO2]/%H M +M?3Q:
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52P4&      4 !0!* 0  X$L

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
